NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-31
Reading ZTS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue growth is slowing — up about 3% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 8%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 54% in its worst 12-month stretch.
View RiskZoetis (ZTS) needs to drive revenue growth with new product approvals to justify its price. Revenue growth has been strong, but the latest earnings report showed a miss. ZTS trades at 12× P/E, below the peer median of 14.5×. The risk is that management is behind on commitments, which could hurt growth. Peer multiples imply a price about 5% below where it trades. This read is provisional.
Trailing returns as of 2026-07-31. ZTS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering ZTS (as of Jul 2026).
Based on 5 Wall Street analysts offering 12-month price targets for ZTS in the last 4 months.
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Threatens: Drive revenue growth with new product approvals
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $77.29
The last 12 months of price, then the range of analyst 12-month targets from today’s $77.29.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Analyst suggests delayed stabilization impacts revenue growth.
Difficult Q1 update raises concerns about future growth.
Cramer's comments suggest competitive pressures.
Downgrade indicates potential revenue growth issues.
New board member may enhance strategic direction.
Earnings growth trailing indicates potential issues.
Acquisition enhances product offerings and growth potential.
